Determinants of antiviral treatment initiation in a hepatitis C-infected population benefiting from universal health care coverage

Canadian Journal of Gastroenterology

Volumn 21, Issue 6, 2007, Pages 355-361

  Moirand, Romain ^a   Bilodeau, Marc ^b,c   Brissette, Suzanne ^d   Bruneau, Julie ^d  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF MONTREAL   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Alcohol intake; Hepatitis C; Interferon treatment; Substance related disorders

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; METHADONE; PEGINTERFERON; RIBAVIRIN;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; HEALTH BEHAVIOR; HEPATITIS C; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; LIVER FIBROSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTPATIENT; PERSONALITY DISORDER; PREVALENCE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TREATMENT REFUSAL;

EID: 34547441386     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/576765     Document Type: Article

References (33)

1. Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: A systematic review. Hepatology 2002;36:S135-44.
2. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237-44.
3. Sherman M, Bain V, Villeneuve JP, et al. The management of chronic viral hepatitis: A Canadian consensus conference 2004. Can J Gastroenterol 2004;18:715-28.
4. Agence Nationale d'Accreditation et d'Evaluation en Sante (ANAES). Consensus conference. Treatment of hepatitis C. Gastroenterol Clin Biol 2002;26:B303-20.
5. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002;36:S3-20.
6. Strader DB. Understudied populations with hepatitis C. Hepatology 2002;36:S226-36.
7. Filoche B. [Treatment of hepatitis C in intravenous drug users.] Gastroenterol Clin Biol 2002;26 Spec No 2:B252-6.
8. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002;36:S210-9.
9. Mathurin P, Canva V, Dharancy S, Paris JC. [Treatment of chronic hepatitis C and alcohol consumption.] Gastroenterol Clin Biol 2002;26:B248-51.
10. Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology 2002;36:S220-5.
11. Jowett SL, Agarwal K, Smith BC, et al. Managing chronic hepatitis C acquired through intravenous drug use. QJM 2001;94:153-8.
12. Cournot M, Glibert A, Castel F, et al. Management of hepatitis C in active drugs users: Experience of an addiction care hepatology unit. Gastroenterol Clin Biol 2004;28:533-9.
13. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001;34:188-93.
14. Dalgard O, Bjoro K, Hellum K, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002;8:45-9.
15. Grando-Lemaire V, Goisset P, Sorge F, et al. [Hepatitis C virus screening in drug users in an addiction out-patient unit.] Gastroenterol Clin Biol 2002;26:1091-6.
16. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;37:443-51.
17. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: An interim analysis. Drug Alcohol Depend 2002;67:117-23.
18. Lucidarme D. [Hepatitis C and drug use: Epidemiology, screening, natural history and treatment.] Gastroenterol Clin Biol 2002;26:B112-20.
19. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
20. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136:288-92.
21. Guyader D, Lefeuvre C, Jacquelinet S, et al. [Epidemiology of hepatitis C virus infection in 1,304 HCV positive patients: Variations according to the origin of transmission and year of diagnosis.] Gastroenterol Clin Biol 1998;22:375-80.
22. Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 2002;34:268-71.
23. Nguyen HA, Miller AI, Dieperink E, et al. Spectrum of disease in US veteran patients with hepatitis C. Am J Gastroenterol 2002;97:1813-20.
24. Shehab TM, Orrego M, Chunduri R, Lok AS. Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol 2003;98:639-44.
25. Carrier N, Laplante J, Bruneau J. Exploring the contingent reality of biomedicine: Injecting drug users, hepatitis C virus and risk. Health, Risk & Society 2005;7:123-40.
26. Clark EC, Yawn BP, Galliher JM, Temte JL, Hickner J. Hepatitis C identification and management by family physicians. Fam Med 2005;37:644-9.
27. Canadian consensus conference on the management of viral hepatitis. Canadian Association for the Study of the Liver (CASL) Consensus Conference Rapporteur Group. Can J Gastroenterol 2000;14(Suppl B):5B-20B.
28. el-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002;123:476-82.
29. Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willenbring ML. Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psychiatry 2004;26:237-40.
30. Kraus MR, Schafer A, Al-Taie O, Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005;12:96-100.
31. Angelino AF, Treisman GJ. Evidence-informed assessment and treatment of depression in HCV and interferon-treated patients. Int Rev Psychiatry 2005;17:471-6.
32. Bini EJ, Brau N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 US veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005;100:1772-9.
33. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002;36:S30-4.